Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5888-5894

  Filipits, Martin ^a   Rudas, Margaretha ^b   Heinzl, Harald ^b   Jakesz, Raimund ^b   Kubista, Ernst ^b   Lax, Sigurd ^d   Schippinger, Walter ^e   Dietze, Otto ^f   Greil, Richard ^f   Stiglbauer, Wolfgang ^g   Kwasny, Werner ^g   Nader, Alexander ^c   Stierer, Michael ^c   Gnant, Michael F X ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HANUSCH HOSPITAL   (Austria)

^d General Hospital Graz West   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f PARACELSUS MEDICAL UNIVERSITY   (Austria)

^g General Hospital Wiener Neustadt   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; CYCLIN D1; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P27; TAMOXIFEN;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, PROGESTERONE; RECURRENCE; SURVIVAL ANALYSIS; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 70349443675     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0728     Document Type: Article

References (50)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677
2. 1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163
3. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-134
4. Ponce-Castaneda MV, Lee MH, Latres E, et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55:1211-1214
5. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685
6. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J 1999;18:5310-5320 (Pubitemid 29465581)
7. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999;18:5321-5333 (Pubitemid 29465582)
8. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-1144 (Pubitemid 35175969)
9. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-1152 (Pubitemid 35175970)
10. 1 arrest. Nat Med 2002;8:1153-1160
11. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005;16:1723-1739
12. St Croix B, Florenes VA, Rak JW, et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996;2:1204-1210
13. Filipits M, Pirker R, Dunant A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007;25:2735-2740 (Pubitemid 47123181)
14. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004;64:3981-3986
15. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Downregulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 2000;97:9042-9046 (Pubitemid 30626670)
16. Donovan JC, Milic A, Slingerland JM. Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 2001;276:40888-40895 (Pubitemid 37373236)
17. Pohl G, Rudas M, Dietze O, et al. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 2003;21:3594-3600 (Pubitemid 46594051)
18. Porter PL, Barlow WE, Yeh IT, et al. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006;98:1723-1731
19. McCallum M, Baker C, Gillespie K, et al. A prognostic index for operable, node-negative breast cancer. Br J Cancer 2004;90:1933-1941 (Pubitemid 38746333)
20. Schmid M, Jakesz R, Samonigg H, et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 2003;21:984-990 (Pubitemid 46594125)
21. Rudas M, Lehnert M, Huynh A, et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 2008;14:1767-1774
22. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551-561 (Pubitemid 19116001)
23. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997;54:201-208 (Pubitemid 27496007)
24. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717
25. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816 (Pubitemid 32880059)
26. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092 (Pubitemid 38298988)
27. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62 (Pubitemid 40082147)
28. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-462 (Pubitemid 41111693)
29. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757 (Pubitemid 43016814)
30. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-570
31. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25-71. (Pubitemid 32173107)
32. Traub F, Mengel M, Luck HJ, Kreipe HH, von Wasielewski R. Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat 2006;99:185-191 (Pubitemid 44268266)
33. +) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-835
34. Nohara T, Ryo T, Iwamoto S, Gon G, Tanigawa N. Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology 2001;60:94-100. (Pubitemid 32041438)
35. Lau R, Grimson R, Sansome C, Tornos C, Moll UM. Low levels of cell cycle inhibitor p27kip1 combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinomas. Int J Oncol 2001;18:17-23.
36. Chappuis PO, Kapusta L, Begin LR, et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 2000;18:4045-4052 (Pubitemid 32038396)
37. Wu J, Shen ZZ, Lu JS, et al. Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer 1999;79:1572-1578 (Pubitemid 29116822)
38. Tsuchiya A, Zhang GJ, Kanno M. Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol 1999;70:230-234 (Pubitemid 29187908)
39. Gillett CE, Smith P, Peters G, Lu X, Barnes DM. Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J Pathol 1999;187:200-206 (Pubitemid 29037049)
40. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997;57:1259-1263 (Pubitemid 27152548)
41. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-225
42. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-230 (Pubitemid 27064710)
43. Ravaioli A, Monti F, Regan MM, et al. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ann Oncol 2008;19:660-668
44. Barnes A, Pinder SE, Bell JA, et al. Expression of p27kip1 in breast cancer and its prognostic significance. J Pathol 2003;201:451-459 (Pubitemid 37408266)
45. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 2001;67:15-22. (Pubitemid 32703384)
46. Barbareschi M, van Tinteren H, Mauri FA, et al. p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 2000;89:236-241 (Pubitemid 30430739)
47. Spataro VJ, Litman H, Viale G, et al. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer 2003;97:1591-1600 (Pubitemid 36350701)
48. Oh YL, Choi JS, Song SY, et al. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int 2001;51:94-99 (Pubitemid 32174734)
49. Faneyte IF, Peterse JL, Van Tinteren H, et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004;10:4457-4463 (Pubitemid 38878889)
50. Leong AC, Hanby AM, Potts HW, et al. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast. Int J Cancer 2000;89:26-31.